IGF-1 LR3

IGF-1 LR3 Against the Native Hormone

UKPWritten and published by UK Peptides2 min readUpdated 4 cited sources

The short answer

Native IGF-1 is 70 residues and binds IGF binding proteins with high affinity. LR3 is 83 residues and largely does not. A recombinant native IGF-1 is an approved medicine. Mecasermin, marketed as Increlex. LR3 is not that molecule and is approved nowhere.

Key facts

Native IGF-1
70 residues, ~7.6 kDa
IGF-1 LR3
83 residues
Native IGFBP binding
High affinity
LR3 IGFBP binding
Substantially reduced
Approved native product
Mecasermin (Increlex), subcutaneous
Approved LR3 product
None

The structural difference

Thirteen extra residues at the N-terminus and one substitution at position 3. That is the whole of it. The folded core and the three disulfide bonds are otherwise the native architecture. A modest change by residue count, aimed at one interaction.

The functional difference

Native IGF-1 in circulation is almost entirely sequestered by binding proteins. LR3 largely escapes that, which raises its free fraction substantially at the same total concentration. The receptor engagement is not different; the availability is.

Research material referenced

IGF-1 LR3 1mg, third-party HPLC tested

Buy IGF-1 LR3 · £49.99

The regulatory difference, which is the important one

Mecasermin is recombinant human IGF-1 with an FDA-approved label, marketed as Increlex and administered subcutaneously. It has been used in severe primary IGF-1 deficiency. Petriczko and colleagues reported on this in 2019, and Denaite and colleagues described patient characteristics and treatment efficacy in Frontiers in Pediatrics in 2024. That is a licensed medicine with an indication and an evidence base.

And LR3 is not it

The approved product is native rhIGF-1. LR3 is an engineered analogue with different binding behaviour, no marketing authorisation anywhere, and no clinical development programme. The existence of an approved IGF-1 medicine does not extend to it in any respect, and conflating the two is the most consequential error available in this category.

Why the modification was not pursued clinically

The binding protein system is not merely an obstacle. It regulates a growth factor with receptors on every tissue. An analogue engineered to bypass that regulation removes a control mechanism rather than a nuisance. Its development context was cell culture, where controlled availability in a dish is the goal and systemic regulation is not a consideration.

Prohibited status applies to both

IGF-1 and its analogues appear on the WADA Prohibited List under class S2, prohibited at all times in and out of competition. That covers native and engineered forms alike.

Frequently asked questions

Is there an approved IGF-1 medicine?

Yes. Mecasermin, marketed as Increlex, is recombinant human IGF-1 administered subcutaneously. It is native rhIGF-1, not LR3.

Does that approval cover LR3?

No. LR3 is a different molecule with different binding behaviour and holds no marketing authorisation anywhere.

Why wasn't LR3 developed clinically?

Its modifications bypass a regulatory system rather than an obstacle. Its development context was cell culture, where systemic regulation is not a consideration.

Continue researching

Related guides and reference material.

Primary sources & clinical trials

Published papers, trial registrations, regulator pages and company announcements. Links open the original.

UKP

Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).

Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.

Corrections log

More IGF-1 LR3 articles

Research use only. The information above is provided for scientific and educational reference. Compounds referenced are not approved for human use and are supplied for in vitro research or reference-material purposes only. No efficacy, safety, or therapeutic claims are made.